1. Identification of 2-(4-N,N-Dimethylaminophenyl)-5-methyl-1-phenethyl-1H-benzimidazole Targeting HIV-1 CA Capsid Protein and Inhibiting HIV-1 Replication in Cellulo. Alvarez, G., L. van Pul, X. Robert, Z. Artía, A.C. van Nuenen, M. Long, N. Sierra, W. Porcal, N.A. Kootstra, and C. Guillon. BMC Pharmacology and Toxicology, 2022. 23(1): 43. PMID[35765101]. PMCID[PMC9241302].
[PubMed]. HIV_06_2022.
2. Novel Naturally Occurring Dipeptides and Single-stranded Oligonucleotide Act as Entry Inhibitors and Exhibit a Strong Synergistic Anti-HIV-1 Profile. Ceña-Diez, R., K. Singh, A.L. Spetz, and A. Sönnerborg. Infectious Diseases and Therapy, 2022. 11(3): p. 1103-1116. PMID[35391633]. PMCID[PMC9124260].
[PubMed]. HIV_06_2022.
3. Islatravir Has a High Barrier to Resistance and Exhibits a Differentiated Resistance Profile from Approved Nucleoside Reverse Transcriptase Inhibitors (NRTIs). Diamond, T.L., W. Ngo, M. Xu, S.L. Goh, S. Rodriguez, M.T. Lai, E. Asante-Appiah, and J.A. Grobler. Antimicrobial Agents and Chemotherapy, 2022. 66(6): e0013322. PMID[35546110]. PMCID[PMC9211433].
[PubMed]. HIV_06_2022.
4. A Kind of HIV-1 Protease Inhibitors Containing Phenols with Antiviral Activity against DRV-Resistant Variants. Hu, S.J., L. Ma, B. Dong, Q. Shan, J.M. Zhou, G.N. Zhang, M.H. Wang, S. Cen, M. Zhu, J.X. Wang, and Y.C. Wang. Bioorganic & Medicinal Chemistry, 2022. 64: 116760. PMID[35483138].
[PubMed]. HIV_06_2022.
5. Structure-based Discovery of Novel NH(2)-Biphenyl-diarylpyrimidines as Potent Non-Nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Safety: From NH(2)-Naphthyl-diarylpyrimidine to NH(2)-Biphenyl-diarylpyrimidine. Jin, X., L.M. Zhao, S. Wang, W.J. Huang, Y.X. Zhang, C. Pannecouque, E. De Clercq, and F.E. Chen. Journal of Medicinal Chemistry, 2022. 65(12): p. 8478-8492. PMID[35649164].
[PubMed]. HIV_06_2022.
6. Development of Novel Dihydrofuro [3,4-d] pyrimidine Derivatives as HIV-1 NNRTIs to Overcome the Highly Resistant Mutant Strains F227L/V106A and K103N/Y181C. Kang, D.W., Y.Y. Sun, D. Feng, S.H. Gao, Z. Wang, L.L. Jing, T. Zhang, X.Y. Jiang, H. Lin, E. De Clercq, C. Pannecouque, P. Zhan, and X.Y. Liu. Journal of Medicinal Chemistry, 2022. 65(3): p. 2458-2470. PMID[35061384].
[PubMed]. HIV_06_2022.
7. Catchet-MS Identifies IKZF1-Targeting Thalidomide Analogues as Novel HIV-1 Latency Reversal Agents. Ne, E., R. Crespo, R. Izquierdo-Lara, S. Rao, S. Koçer, A. Górska, T. van Staveren, T.W. Kan, D. van de Vijver, D. Dekkers, C. Rokx, P. Moulos, P. Hatzis, R.J. Palstra, J. Demmers, and T. Mahmoudi. Nucleic Acids Research, 2022. 50(10): p. 5577-5598. PMID[35640596]. PMCID[PMC9177988].
[PubMed]. HIV_06_2022.
8. Antiviral Activities of HIV-1-specific Human Broadly Neutralizing Antibodies are Isotype-Dependent. Noailly, B., M. Yaugel-Novoa, J. Werquin, F. Jospin, D. Drocourt, T. Bourlet, N. Rochereau, and S. Paul. Vaccines, 2022. 10(6): 903. PMID[35746511]. PMCID[PMC9227833].
[PubMed]. HIV_06_2022.
9. Discovery and Preclinical Profiling of GSK3839919, a Potent HIV-1 Allosteric Integrase Inhibitor. Parcella, K., T. Wang, K. Eastman, Z. Zhang, Z. Yin, M. Patel, Y. Tu, B.Z. Zheng, M.A. Walker, M.G. Saulnier, D. Frennesson, M. Bowsher, E. Gillis, K. Peese, M. Belema, C. Cianci, I.B. Dicker, B. McAuliffe, B. Ding, P. Falk, J. Simmermacher, D.D. Parker, P. Sivaprakasam, K. Kish, H. Lewis, U. Hanumegowda, S. Jenkins, J.F. Kadow, M. Krystal, N.A. Meanwell, and B.N. Naidu. ACS Medicinal Chemistry Letters, 2022. 13(6): p. 972-980. PMID[35707159]. PMCID[PMC9190037].
[PubMed]. HIV_06_2022.
10. Uracil Derivatives as HIV-1 Capsid Protein Inhibitors: Design, in Silico, in Vitro and Cytotoxicity Studies. Ramesh, D., A.K. Mohanty, A. De, B.G. Vijayakumar, A. Sethumadhavan, S.K. Muthuvel, M. Mani, and T. Kannan. RSC Advances, 2022. 12(27): p. 17466-17480. PMID[35765450]. PMCID[PMC9190787].
[PubMed]. HIV_06_2022.
11. In Vitro Susceptibility of HIV-1 CRF02_AG to Temsavir, the Active Compound of the Attachment Inhibitor Fostemsavir. Saladini, F., A. Giannini, F. Giammarino, A. Boccuto, F. Dragoni, I. Vicenti, and M. Zazzi. Journal of Antimicrobial Chemotherapy, 2021. 76(12): p. 3318-3320. PMID[34402509].
[PubMed]. HIV_06_2022.
12. A Novel Class of HIV-1 Inhibitors Targeting the Vpr-induced G2-Arrest in Macrophages by New Yeast- and Cell-Based High-Throughput Screening. Sato, H., T. Murakami, R. Matsuura, M. Abe, S. Matsuoka, Y. Yashiroda, M. Yoshida, H. Akari, Y. Nagasawa, M. Takei, and Y. Aida. Viruses, 2022. 14(6): 1321. PMID[35746791]. PMCID[PMC9227106].
[PubMed]. HIV_06_2022.
13. Human Immunodeficiency Virus: The Potential of Medicinal Plants as Antiretroviral Therapy. Shahzad, M., H. Chen, T. Akhtar, A. Rafi, M.S. Zafar, and Y.T. Zheng. Journal of Medical Virology, 2022. 94(6): p. 2669-2674. PMID[35128696].
[PubMed]. HIV_06_2022.
14. Design of Artificial α-Helical Peptides Targeting Both gp41 Deep Pocket and Subpocket as Potent HIV-1 Fusion Inhibitors. Wang, H., X. Wang, J. Li, Q. Li, S. Feng, L. Lu, C. Wang, and S. Jiang. European Journal of Medicinal Chemistry, 2022. 236: 114336. PMID[35395438].
[PubMed]. HIV_06_2022.
15. Anti-HIV Tigliane-Type Diterpenoids from the Aerial Parts of Wikstroemia lichiangensis. Zhou, D., K. Otsuki, M. Zhang, G. Chen, Z.S. Bai, H. Yu, T. Kikuchi, L. Huang, C.H. Chen, W. Li, and N. Li. Journal of Natural Products, 2022. 85(6): p. 1658-1664. PMID[35698995].
[PubMed]. HIV_06_2022.
16. Synthesis of Hexahydroquinoline-3-carboxamide Derivatives and Their HIV-1 Antiviral Activity. Mohlala, R.L., E.M. Coyanis, M.Q. Fish, and M.L. Bode. Heterocycles, 2022. 104(5): p. 894-916. ISI[000806825300004].
[WOS]. HIV_06_2022.
Patent Citations
17. Preparation of Tetrahydroquinazoline Derivatives as Selective Cytotoxic Agents. Converso, A., D.N. Hunter, A. El Marrouni, A.J. Roecker, A.W. Shaw, W.D. Shipe, C. Wang, D. Wang, and Y. Zhang. Patent. 2022. 2021-US61944 2022125412: 120pp.
[Patent]. HIV_06_2022.
18. Preparation of Tetracyclic Heterocycle Compounds Useful as HIV Integrase Inhibitors. Graham, T.H., T. Yu, Y. Zhang, and J.A. McCauley. Patent. 2022. 2020-17025371 11358711: 98pp , Cont of U S Ser No 447,421.
[Patent]. HIV_06_2022.
19. Synthesis of Inhibitors of Nef Downmodulation for Treating HIV Infections. Sherman, D.H., M.T. McCauley, N. Carney, A.W. Robertson, M.M. Painter, K.L. Collins, A. Tripathi, and A.R. Condren. Patent. 2022. 2021-US63709 2022133031: 87pp.
[Patent]. HIV_06_2022.
20. Preparation of Tuberculatin Analogs as Antiviral Agents. Zhang, H., Y. Zhu, N.Y. Tsang, and Y. Zhao. Patent. 2022. 2021-CN136032 2022135136: 118pp.
[Patent]. HIV_06_2022.